close
close

ADMA Biologics (NASDAQ:ADMA) Shares Set New 52-Week High of $11.28

ADMA Biologics (NASDAQ:ADMA) Shares Set New 52-Week High of .28


ADMA Biologics, Inc. (NASDAQ:ADMA – Get Free Report) stock reached a new 52-week high during trading on Monday. The company traded as high as $11.28 and was last traded at $11.28, with volume of 3,506 shares. The stock previously closed at $11.18.

Wall Street analysts weigh in

A number of brokerages have recently issued reports on ADMA. HC Wainwright raised their price target on ADMA Biologics from $7.50 to $10.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Cantor Fitzgerald raised their price target on ADMA Biologics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, May 10th. Mizuho raised their price target on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, June 20th. Finally, Raymond James raised their price target on ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong buy” rating in a research report on Friday, May 10th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given the company a strong buy rating. Based on data from MarketBeat, ADMA Biologics has a consensus rating of “Buy” and an average price target of $11.00.

Check out our latest analysis on ADMA

ADMA Biologics Stock Return

The company has a current ratio of 5.21, a quick ratio of 1.86, and a debt-to-equity ratio of 0.91. The company’s fifty-day moving average price is $9.11 and its two-hundred-day moving average price is $6.72.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) posted its latest quarterly results on Thursday, May 9. The biotechnology company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.03. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The company had revenue of $81.90 million for the quarter, compared to analyst estimates of $77.28 million. During the same period last year, the company earned ($0.03) earnings per share. The company’s revenue rose 43.9% year over year. Sales analysts expect ADMA Biologics, Inc. will record a profit per share of 0.35 for the current financial year.

Insider transactions at ADMA Biologics

In other news, CEO Adam S. Grossman sold 100,000 shares of the company’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the sale, the CEO now directly owns 2,081,475 shares of the company’s stock, valued at approximately $22,313,412. The transaction was disclosed in a filing with the SEC, available at this hyperlink. Company insiders own 3.70% of the company’s stock.

Institutional inflow and outflow

Several hedge funds have made recent changes to their holdings. Alberta Investment Management Corp increased its holdings in shares of ADMA Biologics by 32.4% in the 4th quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company worth $2,083,000 after acquiring an additional 112,831 shares in the last quarter. GSA Capital Partners LLP increased its stake in shares of ADMA Biologics by 87.7% in the 3rd quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company worth $867,000 after acquiring an additional 113,184 shares during the period. Qube Research & Technologies Ltd increased its stake in shares of ADMA Biologics by 22.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company worth $4,313,000 after purchasing an additional 224,696 shares during the period. American Century Companies Inc. increased its stake in shares of ADMA Biologics by 20.8% in the 3rd quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company worth $17,514,000 after purchasing an additional 840,761 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of ADMA Biologics by 417.3% in the 4th quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company worth $421,000 after purchasing an additional 75,213 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s shares.

Company profile ADMA Biologics

(Get a free report)

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immunoglobulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed Hepatitis B exposures.

Read further



Receive daily news and reviews for ADMA Biologics – Enter your email address below to receive a concise daily digest of the latest news and analyst ratings about ADMA Biologics and related companies with MarketBeat.com’s FREE daily email newsletter.